What is the main business of Stemco?

The main business activity of Stemco focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on August 22, 2018.

Where is the headquarters located?

The headquarters is located at: Osiedle Parkowe 14, 32-083 Balice.

What is the share capital?

The share capital of the company is PLN 50,000 (approx. $13,506).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

How much revenue was generated?

The company reported a revenue of $520 in 2024, which is an increase of 208.9% compared to 2023.

No, in 2024 the company was not profitable, reporting a net loss of $91. For comparison, in 2023 the loss was $3,549, meaning the company reduced its loss by 97.6%.

What is the main operating cost?

The largest operating cost category falls under materials and energy. This category amounted to $610 in 2024, representing 100% of all operating expenses.

Stemcosp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2018-08-22

Share capital

50,000.00 PLN

Registered address

Osiedle Parkowe 14/1, 32-083 Balice, Poland

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 5 of 6 financial statements were filed late (the longest delay 650 days for 2021).

2025not filed
202404/09/2025
202304/09/2025
202225/04/2024
202125/04/2024
202006/05/2022

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.

Industry · Research and experimental development on biotechnology330 / 386

Top 85%

Division · Scientific research and development1,727 / 1,953

Top 88%

Sector · Professional, scientific and technical activities36,507 / 39,213

Top 93%

Voivodeship · Małopolskie42,434 / 46,035

Top 92%

Country · Poland457,757 / 495,860

Top 92%

Results vs industry

Revenue

This companyUSD 519.71MedianUSD 55.24kAverageUSD 2.70m

Net profit

This companyUSD -91.15MedianUSD -1.27kAverageUSD -92.18k

Operating costs

This companyUSD 610.37MedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 26.99kMedianUSD 133.19kAverageUSD 3.03m

Industry

Authorized Representatives

Everhardus Der Tuin – Attorney-in-fact (sole)

Jakub Smorąg – Management Board Member

Manner of representation

Each member of the management board is authorized to submit declarations of will or represent the company independently with respect to transactions whose value does not exceed PLN 50,000.00. Two members of the management board jointly are authorized to submit declarations of will or represent the company with respect to transactions whose value is PLN 50,000.00 or more.

Ownership

Owner	Shares	Share value	Stake
CIBO sp. z o.o.	250	$6,753.11	50%
Mapatruto Holding B.v.	250	$6,753.11	50%

Beneficial owners

Person	Rights

Bank accounts

Was a VAT taxpayer from 2018-09-28 to 2025-06-25.

Reason for removal: Art. 96 ust. 9a pkt 3 (VAT returns showing no transactions filed for 6 consecutive months or 2 quarters)

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
SkinlabP.S.A.	$1,797,229.06	skinlab.pl
EIT Rawmaterials Clc Eastsp. z o.o.	$1,795,803.10	eitrawmaterials.eu
COS LabP.S.A.	$1,028,123.83	coslab.pl
Syventosp. z o.o.	$970,435.47	syvento.com
IntelliseqS.A.	$111,419.60	intelliseq.pl
Przedsiębiorstwo Wielobranżowe Genezasp. z o.o.	$54,163.54	geneza.eu
Medtransfersp. z o.o.	$21,666.01	codete.com
Oncotherics PolandS.A.	$7,565.33	oncotherics.com
Fusiomicasp. z o.o.	$5,263.98	fusiomica.com
Ncage TherapeuticsS.A.	$29.14	ncage.org